Key Takeaways
- 20% revenue growth in a tough season: IIL delivered 20% top-line growth in Q2 FY24 despite an El Nino year that hurt the broader industry and exports, driven by its strategy of focusing on high-margin "Maharatna" products.
- Old inventory overhang cleared: The margin pressure from high-cost raw material inventory, which weighed on profitability in Q4 FY23 and Q1 FY24, is now largely behind the company, putting it back on a level playing field.
- Product pipeline is the growth engine: New launches like Shinwa, Mission, and Torry are scaling rapidly, with Shinwa set to become the company's top product, while a slate of new herbicides targets the upcoming Rabi season.
- Manufacturing capacity build-out underway: The Dahej and Chopanki expansions are complete, a new Gujarat plant will be active by December, and a greenfield project at Sotanala is planned, all aimed at new AI manufacturing and backward integration.
- What to watch next quarter: The ramp-up of new Rabi-season herbicides (Million, Opaque, Nakshatra), the restart of the Dahej plant, and whether the margin recovery gains traction now that the high-cost inventory drag is gone.
Growth Drivers & Product Strategy
- Maharatna focus paying off: The strategy of concentrating on roughly 30 high-potential, value-added "Maharatna and Focused Maharatna" products while cutting unprofitable old generics is the primary engine of the 20% growth.
- New products scaling fast: Shinwa is on track to touch ₹100 cr in gross sales this month and become the #1 product, while Mission is also expected to cross ₹100 cr in gross sales by brand alone. Torry, launched last year, has seen sales multiply this year.
- Rabi season pipeline: Two new wheat herbicides, Million and Opaque, and Nakshatra, a sugarcane herbicide, have been launched for the Rabi season and are expected to support growth. Products launched in the last two years still have market in this season.
- B2B strategy shift: The company is cutting out old generics with low profitability and stiff competition, having announced the discontinuation of six technicals. The new approach is to patent new formulations and bring mixture products into the B2B segment.
- Japanese collaboration products: Pulsor, Hakama, Izuki, Hachiman, Shinwa, and Kunoichi are all moving well, though Izuki was only a partial success due to a very short season.
Rajesh Aggarwal: "I always believe that it is the solution which attracts the customer, not the product."
Margin & Inventory Recovery
- Old inventory pressure resolved: The company took hits from high-cost inventory in Q4 FY23 and Q1 FY24, but most of that inventory was liquidated in Q2. Q2 profitability surpassed the prior year, and the pressure of old inventories is now over.
- Raw material price stability: Raw material prices are settling down and have almost touched a bottom. Management expects the market to rationalize and stabilize at current levels or start moving up.
- Margin growth visibility: Maharatna sales have improved significantly this year and will further improve over the next two years. Margin growth should be visible in both FY25 and FY26 as the product mix continues to shift toward higher-margin specialty products.
- Working capital discipline: The "90, 90, 90 days" strategy (no inventory older than 90 days, exhaust within 90 days, finances under control within 90 days) is playing out well, and the company hopes to maintain or improve its 112-day working capital cycle.
- Write-down not quantified: When asked to quantify the write-down taken in H1 or Q2 from high-cost inventory liquidation, management stated it is very difficult because calculations are not made that way and they have not worked it out.
Rajesh Aggarwal: "I can at the same time say that we have come out the pressure of old inventories what was there on the company. So, now we are on a level playing field where we can make, we can show the performance..."
Manufacturing Capacity Expansion
- Dahej and Chopanki: The Chopanki expansion is already completed, and the Dahej expansion is almost completed. A new project at the Dahej site is ready and expected to start in early December after final approval.
- Dahej fire repair: Repair work from the fire incident was completed at ₹3.5 cr, below the ₹4 cr estimate. An insurance claim will be filed, and the plant is targeting a November 17 restart after routine maintenance.
- Gujarat plant: Will be fully active by December and will roll out more products, including new AIs and backward integration for insecticide technicals. About half a dozen new AI additions are expected from both the Gujarat and Dahej plants.
- Sotanala greenfield: Land has been acquired, and a proposal to invest roughly ₹150 cr is in place. Construction is expected to start in the next calendar year, with the plant active at full strength by early 2025, doing both technical manufacturing and formulation.
- Capacity utilization nuance: Utilization was about 75%+ last fiscal, but the product mix is changing: new-generation technicals produce much lower quantity but much higher value, so utilization metrics will shift.
Export & Competitive Environment
- Difficult export year: Exports faced a very challenging environment due to El Nino, poor demand visibility, and tight financing conditions in different markets.
- Outperforming despite headwinds: In a year of El Nino, competition was not able to match IIL's numbers, and the company still showed 20% growth.
- China competition: The decision to discontinue six technicals was driven by tough competition from China and high price fluctuation. Management noted this competition will persist until there is a correction in policy to encourage domestic manufacturing and discourage imports.
Rajesh Aggarwal: "This competition is always going to adjust, it was always there and it is always going to remain because till there is a correction in our rational policy that we encourage the domestic manufacturing and discourage the imports..."
New Initiatives & Segments
- Biologicals push: The company is targeting the biologicals segment, believing it has significant upcoming potential. Mycoraja Plus is set to launch, and Nirog, a new bio fungicide, is on its way to market.
- OAT JV progress: The first product from the OAT JV is expected to hit the Indian market in two years. The company is waiting for bio-efficacy official trial results before applying for registration.
- Nissan herbicide launch: A monopolistic paddy herbicide from Nissan is expected to launch in the new year.
- Salesforce CRM launched: The CRM was launched during Navaratri, connecting staff with distributors and retailers.
- Distributor clubs: Two new distributor clubs, the Maharatna Club and Ratna Club, have been formed.
- Net worth milestone: Net worth touched ₹1,000 cr for the first time.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Dahej plant restart | Plant to resume operations after routine maintenance | November 17 |
| New Dahej project start | New project at Dahej site to begin operations | Early December (pending final approval) |
| Gujarat plant full activation | Plant to be fully active, rolling out new AIs and backward integration | December |
| Sotanala plant construction | Construction to begin; plant active at full strength | Construction starts next calendar year; plant active early 2025 |
| OAT JV first product | First product to hit the Indian market | Two years |
| Nissan paddy herbicide launch | Monopolistic paddy herbicide launch | New year |
| Margin growth visibility | Margin growth should be visible as Maharatna sales improve | FY25 and FY26 |
| Revenue growth momentum | Significantly higher revenue growth than industry to continue | FY25 and FY26 |
| B2B sales percentage | 25-26% of sales mix maintainable | Next fiscal year |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | ₹696 cr, +20% YoY from ₹583 cr |
| H1 FY24 revenue | ₹1,336 cr, +17% YoY |
| EBITDA | ₹82 cr, +20.6% YoY from ₹68 cr |
| PAT | ₹53 cr, +17.8% YoY from ₹45 cr |
| Interim dividend | ₹3 per share, 30% of face value; record date Nov 10 |
| Maharatna share of B2C sales | 59%, vs 65% in FY23 |
| Maharatna share of H1 sales | 64%, vs 56% in H1 FY23 |
| Insecticides share of sales | 49%, vs 51% in Q2 FY23 |
| Herbicides share of sales | 34%, vs 29% in Q2 FY23 |
| Fungicides share of sales | 13%, vs 16% in Q2 FY23 |
| B2C share of sales | 71% |
| B2B share of sales | 26% |
| Exports share of sales | 3% |
| Working capital days | 112 days, improved from 169 days in FY23 |
| Inventory | below ₹600 cr, reduced from ~₹850 cr |
| Inventory days | 105 days, improved from 227 days in FY23 |
| Borrowing reduction | ~₹100 cr reduction |
| ROCE (annualized, H1) | 16.4%, improved from 6.9% |
| ROE (annualized, H1) | improved from 10.2% (prior year figure not stated for Q2) |
| Sales team strength | crossed 700 |
| Active crop advisors | more than 900 |
| Active distributors | crossed 8,000 |
| Shinwa gross sales | ₹100 cr expected in November |
| Shinwa net sales target (FY24) | ₹150 cr |
| Brands above ₹50 cr in H1 | 11–12 brands |
| Brands expected to cross ₹100 cr gross sales | 3–4 products (Shinwa, Torry, Hachiman, Mission) |
| New product revenue contribution (H1) | ~20% from products launched in last two years |
| Dahej fire loss | ₹3.5 cr actual, vs ₹4 cr estimated |
| Dahej and Chopanki investment (last 3–4 years) | ~₹300 cr |
| Sotanala proposed investment | ~₹150 cr, starting next calendar year |
| Capacity utilization (existing assets) | ~75% in last fiscal |
| Technical asset return target | 5x plus; industry average ~3x |
| South region target achievement | 105% of target |
| South region YoY growth | 15% to 20% state-to-state |
| Potential paddy crop loss | 2.5 to 3 lakh acres in Andhra, Karnataka, Telangana |
| Receivables | ₹611 cr, up from March levels; Q3 collections expected 20%–50% above sales |